During the last decade, several randomised clinical trials have provided an evidence-based paradigm shift from surgical aortic valve replacement (SAVR) towards transcatheter aortic valve implantation (TAVI) for the treatment of patients with symptomatic severe aortic stenosis (AS) at increased surgical risk. Recently, two additional landmark trials comparing TAVI and SAVR in patients at low surgical risk have been published.
The PARTNER 3 trial, sponsored by Edwards Lifesciences, randomised 1,000 patients with severe AS and at low surgical risk in 71 centres in the USA, Canada, Australia/New Zealand, and Japan to undergo either transfemoral TAVI with the balloon-expandable SAPIEN 3 transcatheter heart ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com